Exploring the kinetics of SARS-CoV-2 Marseille-4 variant

In a recent study posted to the medRxiv* preprint server, researchers determined the nature and dynamics of mutations associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) French Marseille-4 variant during 10 months from its onset.

Study: The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Black Queen rule. Image Credit: Lightspring/ShutterstockStudy: The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Black Queen rule. Image Credit: Lightspring/Shutterstock

The study concluded that the heterogenicity associated with a SARS-CoV-2 lineage can possibly predict the end of an outbreak.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

The characteristics of mutations associated with the SARS-CoV-2 variants leading to subsequent waves of the current coronavirus disease 2019 (COVID-19) pandemic are complex. The extinction of epidemics is linked to the development of herd immunity, decrease in viral load, and the implementation of therapeutic interventions such as vaccination. Moreover, sufficient data regarding factors and mechanisms associated with the emergence, transmission, and extinction of SARS-CoV-2 variants are not yet available.

About the study

In the current study, the researchers determined the kinetics of a new SARS-CoV-2 variant, called Marseille-4, identified from minks at IHU Méditerranée Infection, Marseille, France, in July 2020. The Marseille-4 variant has 20 mutations, with 13 specific mutations compared to the Wuhan-Hu-1 isolate and one among the seven non-synonymous mutations in the spike (S) glycoprotein region.

The study participants had the SARS-CoV-2 Marseille-4 variant infection and their clinical and epidemiological data were collected from the Assistance Publique-Hôpitaux de Marseille (APHM) information system.

The researchers investigated the epidemiological origin and characteristics of the Marseille-4 variant. Genetic data through 10 months from the origin to the extinction of this variant in April 2021 gathered via extensive SARS-CoV-2 genomic surveillance was analyzed using next-generation sequencing. Similarly, the 7,453 genomes of Marseille-4 obtained by next-generation sequencing were classified into lineages and subvariants. The truncated and untruncated forms of ORF8 protein were analyzed by generating a structural ORF8 protein model from the PDB 7JTL file.

The emergence, transmission, and disappearance of the SARS-CoV-2 Marseille-4 variant  were determined using these gathered data.

Results

Two subvariants of the SARS-CoV-2 Marseille-4 variant were identified in the study, namely Marseille-4A with 22 lineages from 50 genomes and Marseille-4B. During the study period, 9,616 cases associated with the Marseille-4 infection were identified using specific quantitative polymerase chain reaction (qPCR).

The average lifetime of these two variants was 4.1±1.4 months and during this period, around 4.1±2.6 mutations had developed. The growth rate was 0.010 to 0.173 in Marseille-4A.17 and Marseille-4A.15, respectively, and the average value of the growth rate was 0.079±0.045. All lineages showed a gamma distribution and were associated with the inactivation of ORF7a or ORF7b genes.

The mutations at unpredicted sites led to a new outbreak, and the accumulation of further mutations led to an increase in heterogenicity, diversity, and extinction of all lineages. None of the mutations were predicted to be probably associated with higher transmissibility, apart from those mutations in the S region.

Marseille-4B emerged after the extinction of all Marseille-4A lineages and its ORF8 gene was inhibited by a stop codon. Further, this subvariant was linked to a high number of SARS-CoV-2-associated hospitalizations and mortality, indicating that ORF8 was a non-virulence gene.

Structural analysis of the truncated form of the ORF8 gene confirmed that stop codon-induced large deletions resulted in a distinct protein that does not share any structural resemblance with the original ORF8 dimer. The average detection time for Marseille-4 lineages was around four months.

Conclusions

The study findings characterized the emergence, transmission, and vanishing of the Marseille-4 variant. The study reported heterogeneity of growth rate for various Marseille-4 subvariants and lineages and indicated that the heterogeneity associated with the SARS-CoV-2 lineage might predict the extinction of the outbreak.

Moreover, the finding suggested that SARS-CoV-2 follows the Black Queen hypothesis, stating that the loss of a gene confers a substantial advantage to the organism when the function of the gene can be dispensable.

The inhibition of the Marseille-4 genes suggested that SARS-CoV-2 originated from a distinct animal reservoir, and the ORF8 and ORF7a/b genes were not necessary to function in humans, pangolins, and minks and may be inhibited in them. The data regarding the inhibition of the ORF8 gene was in line with previous reports on several mink lineages and the Alpha variant.

Overall, it was concluded that the accumulation of beneficial mutations led to an increase in viral fitness, whereas non-beneficial mutations are associated with low viral fitness, transmissibility, and extinction of the lineage.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 10 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Shanet Susan Alex

Written by

Shanet Susan Alex

Shanet Susan Alex, a medical writer, based in Kerala, India, is a Doctor of Pharmacy graduate from Kerala University of Health Sciences. Her academic background is in clinical pharmacy and research, and she is passionate about medical writing. Shanet has published papers in the International Journal of Medical Science and Current Research (IJMSCR), the International Journal of Pharmacy (IJP), and the International Journal of Medical Science and Applied Research (IJMSAR). Apart from work, she enjoys listening to music and watching movies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Susan Alex, Shanet. (2023, May 10). Exploring the kinetics of SARS-CoV-2 Marseille-4 variant. News-Medical. Retrieved on October 07, 2024 from https://www.news-medical.net/news/20220111/Exploring-the-kinetics-of-SARS-CoV-2-Marseille-4-variant.aspx.

  • MLA

    Susan Alex, Shanet. "Exploring the kinetics of SARS-CoV-2 Marseille-4 variant". News-Medical. 07 October 2024. <https://www.news-medical.net/news/20220111/Exploring-the-kinetics-of-SARS-CoV-2-Marseille-4-variant.aspx>.

  • Chicago

    Susan Alex, Shanet. "Exploring the kinetics of SARS-CoV-2 Marseille-4 variant". News-Medical. https://www.news-medical.net/news/20220111/Exploring-the-kinetics-of-SARS-CoV-2-Marseille-4-variant.aspx. (accessed October 07, 2024).

  • Harvard

    Susan Alex, Shanet. 2023. Exploring the kinetics of SARS-CoV-2 Marseille-4 variant. News-Medical, viewed 07 October 2024, https://www.news-medical.net/news/20220111/Exploring-the-kinetics-of-SARS-CoV-2-Marseille-4-variant.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 vaccine uptake higher in people with mental illness but drops for those not on medication